title: Dronedarone-current status in management of atrial fibrillation.
abstract: Atrial fibrillation (AF) is the most common of the serious cardiac rhythm disturbances and is responsible for substantial morbidity and mortality. Available drug therapy for AF has modest efficacy and is associated with the risk of life-threatening pro-arrhythmic complications. Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone and a better side effect profile. It is a multichannel blocker with antiadrenergic properties and has been evaluated in both rate and rhythm control strategies in the management of AF. In this review, we discuss the current role of dronedarone in the contemporary management of AF.
authors.affiliation: Department of Cardiology, CARE Hospitals, Nampally, Hyderabad, India.
authors.forename: Gajendra
authors.initials: G
authors.lastname: Manakshe
authors.forename: B Hygriv
authors.initials: BH
authors.lastname: Rao
mesh_terms: D000638:Amiodarone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000401:mortality; D000077764:Dronedarone; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone